| scholarly article | Q13442814 |
| P50 | author | Colin Dormuth | Q42610582 |
| P2093 | author name string | James M Wright | |
| Ken Bassett | |||
| Greg Carney | |||
| Richard L Morrow | |||
| Jenny Sutherland | |||
| P2860 | cites work | Rosiglitazone and cardiovascular risk | Q80969866 |
| Rosiglitazone and cardiovascular risk | Q94583363 | ||
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
| Co-morbidity data in outcomes research: are clinical data derived from administrative databases a reliable alternative to chart review? | Q30593793 | ||
| Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data | Q30664587 | ||
| Using administrative data to measure ambulatory mental health service provision in primary care | Q33206958 | ||
| Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors | Q34563460 | ||
| Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis | Q34686103 | ||
| Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
| A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences | Q36437684 | ||
| Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma | Q36543510 | ||
| Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. | Q36773986 | ||
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
| Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study | Q37310162 | ||
| Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers | Q42610516 | ||
| Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy | Q44433534 | ||
| Thiazolidinediones and clinical outcomes in type 2 diabetes | Q45329033 | ||
| Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. | Q46020139 | ||
| New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm | Q46471450 | ||
| Rosiglitazone and cardiovascular risk. | Q51906530 | ||
| Segmented regression analysis of interrupted time series studies in medication use research | Q74601008 | ||
| Rosiglitazone no longer recommended | Q79787840 | ||
| The record on rosiglitazone and the risk of myocardial infarction | Q80433580 | ||
| P433 | issue | 1 | |
| P921 | main subject | (RS)-rosiglitazone | Q424771 |
| P304 | page(s) | e50-9 | |
| P577 | publication date | 2010-03-16 | |
| P1433 | published in | Open Medicine | Q2025726 |
| P1476 | title | Impact of rosiglitazone meta-analysis on use of glucose-lowering medications | |
| P478 | volume | 4 |
| Q34623567 | Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010. |
| Q35792497 | Rosiglitazone use and associated adverse event rates in Canada: an updated analysis |
| Q24604853 | State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning |
Search more.